Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
Identifieur interne : 000533 ( Main/Exploration ); précédent : 000532; suivant : 000534Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
Auteurs : Larisa Rudenko [Russie] ; Irina Isakova-SivakSource :
- Expert review of vaccines [ 1744-8395 ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Essais cliniques comme sujet, Grippe humaine (), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Pandémies, Protection civile (), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (isolement et purification), Vaccins atténués (administration et posologie), Vaccins atténués (effets indésirables), Vaccins atténués (immunologie), Vaccins atténués (isolement et purification), Virus de la grippe A (immunologie), Virus de la grippe A (isolement et purification), Évaluation préclinique de médicament.
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués.
- effets indésirables : Vaccins antigrippaux, Vaccins atténués.
- immunologie : Vaccins antigrippaux, Vaccins atténués, Virus de la grippe A.
- isolement et purification : Vaccins antigrippaux, Vaccins atténués, Virus de la grippe A.
- virologie : Grippe humaine.
- épidémiologie : Grippe humaine.
- Animaux, Essais cliniques comme sujet, Grippe humaine, Humains, Pandémies, Protection civile, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Animals, Civil Defense (methods), Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Influenza A virus (immunology), Influenza A virus (isolation & purification), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza Vaccines (isolation & purification), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Pandemics, Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects), Vaccines, Attenuated (immunology), Vaccines, Attenuated (isolation & purification).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated.
- epidemiology : Influenza, Human.
- immunology : Influenza A virus, Influenza Vaccines, Vaccines, Attenuated.
- isolation & purification : Influenza A virus, Influenza Vaccines, Vaccines, Attenuated.
- methods : Civil Defense.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Pandemics.
Abstract
Continuously evolving avian influenza viruses pose a constant threat to the human public health. In response to this threat, a number of pandemic vaccine candidates have been prepared and evaluated in animal models and clinical trials. This review summarizes the data from the development and preclinical and clinical evaluation of pandemic live attenuated influenza vaccines (LAIV) based on Russian master donor virus A/Leningrad/134/17/57. LAIV candidates of H5N1, H5N2, H7N3, H1N1 and H2N2 subtypes were safe, immunogenic and protected animals from challenge with homologous and heterologous viruses. Clinical trials of the pandemic LAIVs demonstrated their safety and immunogenicity for healthy adult volunteers. The vaccine viruses were infectious, genetically stable and did not transmit to unvaccinated contacts. In addition, here we discuss criteria for the assessment of pandemic LAIV immunogenicity and efficacy necessary for their licensure.
DOI: 10.1586/14760584.2015.979159
PubMed: 25555687
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000085
- to stream PubMed, to step Curation: 000085
- to stream PubMed, to step Checkpoint: 000065
- to stream Ncbi, to step Merge: 000B24
- to stream Ncbi, to step Curation: 000B24
- to stream Ncbi, to step Checkpoint: 000B24
- to stream Main, to step Merge: 000534
- to stream Main, to step Curation: 000533
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.</title><author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg, 195220, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg, 195220</wicri:regionArea><wicri:noRegion>195220</wicri:noRegion></affiliation></author><author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25555687</idno><idno type="pmid">25555687</idno><idno type="doi">10.1586/14760584.2015.979159</idno><idno type="wicri:Area/PubMed/Corpus">000085</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000085</idno><idno type="wicri:Area/PubMed/Curation">000085</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000085</idno><idno type="wicri:Area/PubMed/Checkpoint">000065</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000065</idno><idno type="wicri:Area/Ncbi/Merge">000B24</idno><idno type="wicri:Area/Ncbi/Curation">000B24</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B24</idno><idno type="wicri:Area/Main/Merge">000534</idno><idno type="wicri:Area/Main/Curation">000533</idno><idno type="wicri:Area/Main/Exploration">000533</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.</title><author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg, 195220, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg, 195220</wicri:regionArea><wicri:noRegion>195220</wicri:noRegion></affiliation></author><author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name></author></analytic><series><title level="j">Expert review of vaccines</title><idno type="eISSN">1744-8395</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Civil Defense (methods)</term><term>Clinical Trials as Topic</term><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Influenza A virus (immunology)</term><term>Influenza A virus (isolation & purification)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (isolation & purification)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Pandemics</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (adverse effects)</term><term>Vaccines, Attenuated (immunology)</term><term>Vaccines, Attenuated (isolation & purification)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Essais cliniques comme sujet</term><term>Grippe humaine ()</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Pandémies</term><term>Protection civile ()</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (isolement et purification)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins atténués (effets indésirables)</term><term>Vaccins atténués (immunologie)</term><term>Vaccins atténués (isolement et purification)</term><term>Virus de la grippe A (immunologie)</term><term>Virus de la grippe A (isolement et purification)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Civil Defense</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Essais cliniques comme sujet</term><term>Grippe humaine</term><term>Humains</term><term>Pandémies</term><term>Protection civile</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuously evolving avian influenza viruses pose a constant threat to the human public health. In response to this threat, a number of pandemic vaccine candidates have been prepared and evaluated in animal models and clinical trials. This review summarizes the data from the development and preclinical and clinical evaluation of pandemic live attenuated influenza vaccines (LAIV) based on Russian master donor virus A/Leningrad/134/17/57. LAIV candidates of H5N1, H5N2, H7N3, H1N1 and H2N2 subtypes were safe, immunogenic and protected animals from challenge with homologous and heterologous viruses. Clinical trials of the pandemic LAIVs demonstrated their safety and immunogenicity for healthy adult volunteers. The vaccine viruses were infectious, genetically stable and did not transmit to unvaccinated contacts. In addition, here we discuss criteria for the assessment of pandemic LAIV immunogenicity and efficacy necessary for their licensure. </div></front></TEI><affiliations><list><country><li>Russie</li></country></list><tree><noCountry><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name></noCountry><country name="Russie"><noRegion><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000533 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000533 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25555687
|texte= Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25555687" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |